UI Hospitals and Clinics

Clinical Trial Details

Short Title
Treatment for Very Low Favorable Histology Wilms Tumor
Official Title

Treatment for Very Low Favorable Histology Wilms Tumor


Participants in this research study have a favorable histology Wilms tumor that has some risk of returning after treatment. The purpose of this research study is to find out if subjects with a higher risk of having their tumor return will benefit from the addition of doxorubicin or the current standard treatment. Approximately 5 people will take part in this study at the University of Iowa. Study involvement will last for 25 weeks and will have follow-up examinations and tests for about 5 years.

Start Date
February 18, 2009
End Date
August 17, 2013
Gender Preference
Age Group
0 - 99 years
Principal Investigator
Ayman El-Sheikh, MD
Contact Info

Victoria Scaccia, 319-356-7875

Department or Field of Study
AREN0532 ; cancer ; doxorubicin ; el-sheikh ; IRB#200812777 ; pediatric ; phase 3 ; phase III ; Wilms tumor ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.